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Abstract 40 
Background.  This study aimed to evaluate the efficacy and safety of continuous antimicrobial infusion 41 
using elastomeric pumps in an outpatient setting, whilst simultaneously documenting circulating 42 
antibiotic concentration exposure achieved with this mode of administration. 43 
Methods. Clinical outcomes, adverse events and antibiotic plasma concentrations were recorded for all 44 
patients treated by continuous infusion with elastomeric pumps at the outpatient parenteral 45 
antimicrobial therapy (OPAT) unit of the University Hospital of Lausanne between December 2013 and 46 
January 2017.  47 
Results. One hundred and fifty outpatients were treated by continuous intravenous infusions using 48 
flucloxacillin (70 patients), cefepime (36), vancomycin (32) and piperacilin/tazobactam (12). The 49 
calculated free fractions of each antibiotic were above the epidemiological cut-off values for resistance 50 
(ECOFF) of the treated microorganisms in 92% of the measurements. Cure was achieved in one hundred 51 
and forty three patients (95%) 3 months after the end of treatment. Four patients needed unexpected 52 
readmission, three patients had a relapse. In none of the patients with unsuccessful treatment was the 53 
ratio of free antibiotic plasma concentration / ECOFF below one. Fifteen patients (10%) had an adverse 54 
event, none of them being of severity grade 4 or 5.  55 
Conclusion. Continuous infusions of flucloxacillin, cefepime, vancomycin and piperacillin/tazobactam 56 
using elastomeric pumps seem to be an effective and safe approach to treat outpatients. The number of 57 
treatment successes was very high and adverse events occurred at a similar rate as reported by other 58 
OPAT centers. The measured antibiotic plasma concentrations confirmed adequate drug concentration 59 
exposure for the vast majority of patients. 60 
  61 
 Background 62 
Some patients with difficult-to-treat infections require intravenous antibiotics, often for a prolonged 63 
duration, but are otherwise well enough to be treated as outpatients. Considering the numerous 64 
advantages of ambulatory treatment, outpatient parenteral antimicrobial therapy (OPAT) centers were 65 
initially established in the USA, and the concept has now spread to many other countries, notably in 66 
Europe.  67 
 68 
In this context, elastomeric pumps allow for the continuous infusion of antibiotics with time-dependent 69 
killing mechanisms and short half-lives, which would otherwise require several injections per day. As the 70 
pumps are changed just once a day, either by the patient himself or by a nurse, it allows a greater 71 
autonomy for the patient and decreases the burden on the health care system. It avoids multiple daily 72 
interventions by the nurses of the OPAT unit or the home health care services. In some instances, it 73 
enables treatment continuation with a first line agent, which is otherwise difficult to administer on an 74 
outpatient basis without a pump. It is probably cost-effective, although a formal economic evaluation 75 
has still to be done.  Finally, in a previous study, we showed that acceptance and satisfaction was very 76 
high among patients receiving antibiotics via elastomeric pumps.1  77 
 78 
The potential degradation of the antibiotics in these devices limits their use. The manufacturers of 79 
elastomeric pumps have published antibiotic stability data, and most reference documents and 80 
guidelines are based on these data from the manufacturers.2 There are however several limitations to 81 
these stability data. Firstly, there has been almost no independent verification of these data. Secondly, 82 
these data were generated under standardized laboratory conditions, which do not necessarily reflect 83 
real-life situations. Thirdly, the tests did not always evaluate antimicrobial stabilities at concentrations 84 
and at time points relevant for clinical situations. The BSAC therefore concluded that stability data for all 85 
major, most frequently used antibiotics administered via elastomeric pumps, are insufficient.3 86 
 87 
In a previous study, we evaluated the temperature variations of solutions in elastomeric pumps under 88 
real-life conditions and showed that these temperatures can exceed 30°C.4 In the same study we also 89 
measured the degradation of flucloxacillin, cefazolin, cefepime and piperacillin/tazobactam in 90 
elastomeric pumps worn under real-life conditions. We concluded that the degradation of these 91 
antibiotics was acceptable despite the occurrence of excessive temperatures.  92 
 93 
The aim of the present study was to evaluate the efficacy and safety of continuous infusions with 94 
elastomeric pumps for outpatient parenteral antimicrobial therapy and to measure circulating antibiotic 95 
concentration exposure achieved with this mode of administration. 96 
 97 
Methods 98 
We prospectively collected data from all patients treated by continuous infusion with elastomeric 99 
pumps by the OPAT unit of the University Hospital of Lausanne between December 2013 and January 100 
2017. We obtained informed consent for all patients. An analysis of the patients treated by continuous 101 
infusions of amoxicillin using elastomeric pumps was published previously, and these patients were 102 
therefore not included in this report.5  103 
 104 
Elastomeric pumps of the brand Easypump II 270-27 (BBraun, Melsungen, Germany) were prepared 105 
under laminar flow by the staff of a single pharmacy. Pumps were prepared for up to 7 days and patients 106 
were instructed to keep them in their fridge before use. A PICC-line (Power Picc, Becton Dickinson, 107 
Eysins, Switzerland) was used for venous access in all patients. An infectious disease specialist evaluated 108 
 the patients weekly or more frequently  if indicated. Patients were encouraged to change their 109 
elastomeric pumps by themselves (self-administration). OPAT nurses or home health care nurses 110 
changed the pumps only if the patient was reluctant or if the health professional considered the patient 111 
unable to do self-administration.  112 
 113 
Socio-demographic and clinical data were recorded, namely gender, age, site of infection (osteo-114 
articular, endovascular, urinary, pulmonary, catheter-related, abdominal, skin and soft tissue, ear nose  115 
and throat, central nervous system), microorganisms responsible of the infection, antimicrobial 116 
treatment (flucloxacillin, cefepime, vancomycin, piperacillin/tazobactam, other), type of administration 117 
(self-administration, administration by a home health care nurse,  administration at the OPAT clinic, 118 
mixed) and duration of treatment. 119 
 120 
Continuous infusion was started one hour after a loading dose or one hour after the last intermittent 121 
dose administered at the hospital. We measured antibiotic plasma concentrations after at least 48 hours 122 
of continuous infusion. As continuous infusion is expected to generate a steady concentration plateau, 123 
we measured plasma concentration at unselected times during treatment. Blood was drawn at the OPAT 124 
unit once a week or more frequently in case of discrepant values or unstable renal function. 125 
Antimicrobial drug concentrations in plasma were measured by a validated method of liquid 126 
chromatography coupled to tandem mass spectrometry using stable isotopically-labelled Internal 127 
Standards and matrix-matched calibration samples.6 For each patient with an identified infectious agent, 128 
we calculated the ratio of antibiotic plasma concentration corrected for the free fraction of the 129 
antibiotic, divided by the epidemiological cut-off value of resistance (ECOFF) of the bacteria treated. The 130 
plasma free fraction of antibiotics used in these calculations were extracted from the summaries of 131 
product characteristics and were as follows: flucloxacillin = 10%, vancomycin = 70%, cefepime = 80%, 132 
and piperacillin = 80%. The ECOFF values were extracted from the EUCAST website.7  133 
 134 
We assessed outcomes at the end of OPAT treatment and 3 months later using the hospital records. The 135 
patients were considered as cured in case of absence of fever, no local signs of infection at the end of 136 
the treatment as assessed by an infectious disease specialist and no unplanned readmission to our 137 
hospital for the same cause within 3 months after the end of treatment, Unplanned readmissions during 138 
OPAT, relapses of infection during or after end of OPAT, or deaths during or within the 3 months after 139 
the end of OPAT were considered as treatment failures. Expected readmissions, such as for example for 140 
an elective change of a prosthesis, were not considered as treatment failures.  141 
 142 
Adverse events were classified according to the Safety Reporting Requirements for INDs and BA/BE 143 
Studies FDA Guidance.8 Grade classification (grade 1 to 5) was used as recommended by the Common 144 
Terminology Criteria for Adverse Events (CTCAE).9 We recorded adverse events during treatment and for 145 
the following 3 months.  146 
 147 
All analyses were descriptive. The data were collected in Microsoft Excel and analyzed using Stata 14.0, 148 
through univariate analyses. Graphs were designed using Graphpad 6.0.  Ethical approval was granted 149 
by the Ethics Committee of the Canton of Vaud (protocol number 34/14). The study was registered 150 
under ClinicalTrials.gov identifier NCT03221140.  151 
 152 
Results 153 
Among the 545 patients treated at the OPAT unit during the study period, 150 were included in the 154 
analysis (Figure 1). We excluded 395 patients for the following reasons: 366 were treated with 155 
 antibiotics other than flucloxacillin, cefepime, vancomycin or piperacillin/tazobactam; 9 were still on 156 
treatment at the time of the study period; 20 did not receive the antibiotics by continuous infusion. 157 
 158 
The 150 included patients treated by continuous intravenous infusions were mostly men (72%), with a 159 
median age of 59 years (range = 16-93). Table S1 shows the microorganisms involved in the infections. 160 
Table 1 summarizes the sites of infection and details of the treatment. Of note, 73 patients (53%) were 161 
treated for osteo-articular infections. The patients were treated with flucloxacillin (70 patients), 162 
cefepime (36), vancomycin (32) and piperacillin/tazobactam (12). Duration of treatment varied from 2 to 163 
104 days, with a median of 13 days. Self-administration was performed by 82% of the patients. 164 
Treatment was administered by home health care nurses (13%) or by nurses at the OPAT unit (5%) for 165 
patients unable or unwilling to do self-administration. 166 
 167 
 143 patients (95%) were cured 3 months after the end of treatment. There were 4 unexpected 168 
readmissions during treatment and 3 relapses within 3 months after treatment completion. Table 2 169 
shows the characteristics and the type of infections of these patients considered to have experienced 170 
treatment failure.  171 
 172 
Two hundred and twelve plasma antibiotic concentrations were measured in 101 patients and the mean 173 
concentrations (± standard deviation) for each antibiotic were as follows: flucloxacillin = 36 mg/L (± 174 
15.2), cefepime = 21.3 mg/L (± 12.1), vancomycin = 17.2 mg/L (±5.3), piperacillin = 25.8 mg/L (± 15.7). 175 
Figure 1 shows the ratio of the calculated free antibiotic plasma concentrations divided by the ECOFF of 176 
the microorganisms treated. This ratio was ≥1 for 180 of 196 measurements (92%): flucloxacillin 62/71 177 
(87%), vancomycin 70/71 (99%), cefepime 36/40 (90%), and piperacillin 12/14 (86%). Ten plasma drug 178 
concentrations were measured in 6 of the 7 patients who experienced a treatment failure. The ratio of 179 
free antibiotic plasma concentration / ECOFF was ≥ 1 for all the measurements in these 6 patients. 180 
 181 
Among the 150 patients enrolled, 16 patients (11%) experienced an adverse event (Table S2), which 182 
included 2 cases of grade 3, namely hospitalization for hypokalemia and febrile agranulocytosis. The 183 
other adverse events were 3 cases of grade 2 (2 cases of catheter-related thrombosis and 1 catheter-184 
related infection), and 11 cases of grade 1 [neutropenia (4 cases), rash (2), cholestasis (1), 185 
thrombocytosis (1), catheter-related superficial thrombosis (1), diarrhea (1), and renal failure (1)]. None 186 
of the adverse events were of grade 4 or 5.  187 
 188 
Discussion 189 
Elastomeric devices have mainly been used for the ambulatory administration of oncological 190 
treatments. Several guidelines mention their possible use in the context of OPAT.10, 11 The use of 191 
elastomeric pumps facilitates the ambulatory management of patients and favors the use of first line 192 
anti-microbial agents. We thus expect a knock on effect on cure rates and benefits from a perspective of 193 
antimicrobial stewardship. The main concern is that antibiotic degradation in such devices could exceed 194 
the recommended limit of 10% and that this could lead to treatment failures and/or an excess of 195 
adverse events due to possible toxic degradation products of the antibiotics.  196 
  197 
In the current study, we verified the circulating antibiotic plasma concentrations of patients treated by 198 
antibiotics administered continuously over 24 hours via elastomeric pumps. As shown in figure 1 the 199 
calculated free antibiotic plasma concentrations were above the ECOFF of the bacteria to be treated in 200 
92% of the measurements (86%-99% depending on the antibiotics).  201 
 We chose to use for this analysis the ECOFF values, because the true MIC of the microorganisms was 202 
only known in a small number of patients. As the MICs of bacteria follow a Gauss-shaped curve, free 203 
antibiotic concentrations were above the actual MIC of the microorganisms in the vast majority of cases, 204 
even when plasma drug concentrations were measured slightly below the population target. 205 
 206 
None of the patients with treatment failures had a low ratio of free antibiotic plasma concentration / 207 
ECOFF. In addition, the intermittent administration of the same antibiotics at similar daily dosage would 208 
have resulted in a much less favorable pharmacokinetic profile, with antibiotic residual levels dropping 209 
frequently below the ECOFF values of the microorganisms. 210 
 211 
As shown in figure 1 there was a significant intra-patient variability of the measured antibiotic plasma 212 
concentrations. While random sampling time assumes a steady infusion rate, elastomeric pumps show 213 
variable infusion rate, sometimes leading to premature completion of the infusion.12  Thus, blood 214 
concentrations measured early or late during the infusion period may be higher or lower than theoretically 215 
expected. Degradation of antibiotics in the elastomeric pumps could also have contributed to variations 216 
in antibiotic plasma concentrations depending on the time the blood was drawn. The time of the blood 217 
sampling was not recorded, therefore it was not possible to verify if lower plasma concentrations were 218 
systematically at the end of the infusion periods. Yet this antibiotic degradation in the pumps was shown 219 
to be at most limited for the antibiotics used.4 220 
 221 
The proportion of favorable outcomes in this cohort was very high. Several groups have reported cure 222 
rates of cohorts of OPAT patients. In a comprehensive review that examined the outcomes of global 223 
OPAT programs, the cure rates reported in the included studies varied from 72.5% and 95%.13 There are 224 
two main issues when comparing different studies. Firstly, there are no common outcome definitions 225 
and the time of evaluation is often variable. Secondly, the case mix is very different between the 226 
cohorts, due to significant heterogeneity of patients, some have a large proportion of patients with easy 227 
to treat infections such as skin and soft tissue infections, whilst others have a larger proportion of more 228 
difficult to treat infections such as bone and joint infections.  In our cohort, the cure rate at 3 months 229 
after end of treatment was 95%, despite a proportion of joint and bone infections greater than 50%. 230 
Patients were only considered as cured if there were no more signs of infection at the end of antibiotic 231 
treatment and if there was no relapse or readmission to the hospital for the same infectious problem 232 
within 3 months.  This definition of cure is more stringent than in any other studies to date, where the 233 
outcome is usually evaluated at the end of the treatment.  234 
 235 
Possible explanations for these good outcomes are the low age of the study population (median of 59 236 
years) probably indicative of a population without multiple comorbidities, or the absence of multidrug-237 
resistant bacteria. In addition, it could also suggest high efficacy of continuous antibiotic infusion. 238 
 239 
The effectiveness of continuous administration of antibiotics has been only investigated in the acute 240 
care setting, and its superiority has not been demonstrated conclusively over the discontinuous 241 
administration of antibiotics.14 The median duration of continuous antimicrobial treatment of our 242 
patients was 13 days and may have been more appropriate to show a benefit of continuous 243 
antimicrobial administration. Our results may even support the hypothesis that continuous antimicrobial 244 
administration could be particularly effective for deep, difficult-to-treat infections. For example, in this 245 
cohort, the successful outcome of the patients treated for the notoriously difficult to treat osteo-246 
articular infections was 96% (70/73 patients). Other OPAT units treating population of patients with a 247 
large percentage with bone and joint infections (as much as 43 -60% of them) have reported slightly less 248 
favorable outcomes with cure rates of 86-93%.15-18 These data should prompt the initiation of a 249 
 randomized trial comparing OPAT with continuous infusions versus OPAT with intermittent 250 
administration of antibiotics, to formally confirm the favorable outcomes of continuous OPAT with 251 
elastomeric devices. 252 
 253 
Nowadays there is a  trend  towards shorter durations of intravenous antibiotic treatments as currently 254 
investigated for bone and joint infections in the OVIVA trial.19 The median duration of OPAT of 13 days in 255 
this study could be considered as relatively long, considering that all patients had already received 256 
intravenous antibiotics during their hospital stay. The reasons for these relatively long intravenous 257 
treatment durations were not analyzed in detail, but we postulate that many of our patients had 258 
particularly difficult to treat infections. We emphasize that we do not advocate prolonged treatments 259 
with intravenous antibiotics. For example, at our institution the recommended duration of intravenous 260 
treatment is 14 days for uncomplicated bone and joint infections, including prosthetic joint infections.  261 
 262 
Sixteen (11%), mostly minor, adverse events were observed. The adverse events were mostly expected 263 
side effects of the administered drugs. We did not observe adverse events suggestive of 264 
hypersensitivity, for which the reported potentially toxic degradation products of the antibiotics could 265 
be incriminated. In this observational study, adverse events were not associated with excessive or 266 
insufficient plasma antibiotic concentrations.  267 
 268 
As limitations of this study the statistical power was insufficient to draw any firm conclusion on whether 269 
the ratio of free concentration over the ECOFF of the bacteria to be treated would be a predictor for 270 
either treatment failure or adverse reactions. Moreover, even if continuous infusion is generally 271 
expected to improve tissue distribution, antibiotic levels in tissues may differ from blood. Consequently, 272 
antibiotic plasma levels may not guarantee sufficient tissue exposure, known for high inter-patient 273 
variability.  A further limitation is the fact that free antibiotic concentrations were extrapolated from the 274 
fixed free fraction reference values available in the summary of product characteristics. The free fraction 275 
of drugs is however known to be difficult to establish and is characterized by significant inter-individual 276 
variability, being notably affected by patients’ pathophysiological conditions, among other causes. 277 
Finally, the number of patients with unfavorable outcome might have been underestimated. We only 278 
verified the occurrence of relapses and readmissions on the basis of the records of our own hospital. 279 
Some patients may have consulted at other hospitals, although we do not think that this represents a 280 
significant number of patients. 281 
 282 
In conclusion, these data suggest that OPAT using elastomeric pumps for the continuous administration 283 
of the 4 above-mentioned antibiotics is efficacious and safe. Drug concentration measurements, 284 
considered as a proxy for efficacy, confirm adequate circulating antibiotic exposures consistent with the 285 
observed high rate of therapeutic success.  286 
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 Table 1. Characteristics of the patients and their treatment     340 
Demographic characteristics:    
Male 72% (108) 
Median age in years (range)                   59 (16-93) 
Site of infection:   
Osteo-articular  53% (79) 
Endovascular 12% (18) 
Urinary 11% (16) 
Pulmonary 9% (13) 
Catheter-related 5% (8) 
Abdominal 3% (5) 
Skin and soft tissue 3% (5) 
Ear, Nose and Throat 3% (4) 
Central nervous system 1% (2) 
Antibiotics used  
Flucloxacillin 47% (70) 
Cefepime 24% (36) 
Vancomycin 21% (32) 
Piperacillin/tazobactam 8% (12) 
Administration of antibiotics:  
Self-administration 82% (123) 
Home health nurse 13% (19) 
OPAT unit 4% (6) 
Mixed 1% (2) 
Median duration of treatment (days)           13 (range 2-104) 
  341 
    
    
  
  
    
   
   
  
  
Table 2. Patients with treatment failure (unplanned readmission during treatment or relapse of infection within 3 months of the end of 342 
treatment)    343 
344 
Sex  Age  Type of 
infection 
Microorganism Days of 
OPAT 
Antibiotic  Type of 
OPAT 
failure  
Management of failure 
F  59 Prosthetic joint 
infection 
MSSA 8 Flucloxacillin  Unplanned 
readmission  
Surgery and prolongation of antibiotic 
treatment with flucloxacillin 
M  58 Infection of a 
vascular 
prothesis 
Staphylococcus lugdunensis 
and epidermidis, 
Corynebacterium spp 
7 Flucloxacillin  Unplanned 
readmission 
Surgery and change of antibiotic adapted 
to new culture results   
F  54 Iliac bone 
infection post 
biopsy 
MRSA 16 Vancomycin  Unplanned 
readmission 
Surgery and change of antibiotic adapted 
to new culture results.  
M  54 Pelvic abcess  Polymicrobial infection 11 Cefepime  Unplanned 
readmission 
Palliative care and prolongation of 
antibiotic treatment. Death from 
oncological disease.   
M  50 Osteitis of the 
olecranon 
MSSA 15 Flucloxacillin  Relapse Surgery and new course of flucloxacillin 
M  51 Part-A-Cath 
infection  
Staphylococcus capitis 3 Vancomycin  Relapse Removal of Port-A-Cath and new course 
of antibiotics 
M  58 Prostatitis  Pseudomonas aeruginosa 24 Piperacillin/  
Tazobactam  
Relapse New course of piperacillin/tazobactam 
 Figure 1. Ratio of the free antibiotic plasma concentration over the ECOFF of the bacteria to be treated 345 
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